Open Access

Construction of in vitro patient‑derived tumor models to evaluate anticancer agents and cancer immunotherapy

  • Authors:
    • Nobuhiko Takahashi
    • Arisa Higa
    • Gen Hiyama
    • Hirosumi Tamura
    • Hirotaka Hoshi
    • Yuu Dobashi
    • Kiyoaki Katahira
    • Hiroya Ishihara
    • Kosuke Takagi
    • Kazuhito Goda
    • Naoyuki Okabe
    • Satoshi Muto
    • Hiroyuki Suzuki
    • Kenju Shimomura
    • Shinya Watanabe
    • Motoki Takagi
  • View Affiliations

  • Published online on: March 22, 2021     https://doi.org/10.3892/ol.2021.12667
  • Article Number: 406
  • Copyright: © Takahashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

An in vitro assay system using patient‑derived tumor models represents a promising preclinical cancer model that replicates the disease better than traditional cell culture models. Patient‑derived tumor organoid (PDO) and patient‑derived tumor xenograft (PDX) models have been previously established from different types of human tumors to recapitulate accurately and efficiently their tissue architecture and function. However, these models have low throughput and are challenging to construct. Thus, the present study aimed to establish a simple in vitro high‑throughput assay system using PDO and PDX models. Furthermore, the current study aimed to evaluate different classes of anticancer drugs, including chemotherapeutic, molecular targeted and antibody drugs, using PDO and PDX models. First, an in vitro high‑throughput assay system was constructed using PDO and PDX established from solid and hematopoietic tumors cultured in 384‑well plates to evaluate anticancer agents. In addition, an in vitro evaluation system of the immune response was developed using PDO and PDX. Novel cancer immunotherapeutic agents with marked efficacy have been used against various types of tumor. Thus, there is an urgent need for in vitro functional potency assays that can simulate the complex interaction of immune cells with tumor cells and can rapidly test the efficacy of different immunotherapies or antibody drugs. An evaluation system for the antibody‑dependent cellular cytotoxic activity of anti‑epidermal growth factor receptor antibody and the cytotoxic activity of activated lymphocytes, such as cytotoxic T lymphocytes and natural killer cells, was constructed. Moreover, immune response assay systems with bispecific T‑cell engagers were developed using effector cells. The present results demonstrated that in vitro assay systems using PDO and PDX may be suitable for evaluating anticancer agents and immunotherapy potency with high reproducibility and simplicity.
View Figures
View References

Related Articles

Journal Cover

May-2021
Volume 21 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takahashi N, Higa A, Hiyama G, Tamura H, Hoshi H, Dobashi Y, Katahira K, Ishihara H, Takagi K, Goda K, Goda K, et al: Construction of <em>in vitro</em> patient‑derived tumor models to evaluate anticancer agents and cancer immunotherapy. Oncol Lett 21: 406, 2021
APA
Takahashi, N., Higa, A., Hiyama, G., Tamura, H., Hoshi, H., Dobashi, Y. ... Takagi, M. (2021). Construction of <em>in vitro</em> patient‑derived tumor models to evaluate anticancer agents and cancer immunotherapy. Oncology Letters, 21, 406. https://doi.org/10.3892/ol.2021.12667
MLA
Takahashi, N., Higa, A., Hiyama, G., Tamura, H., Hoshi, H., Dobashi, Y., Katahira, K., Ishihara, H., Takagi, K., Goda, K., Okabe, N., Muto, S., Suzuki, H., Shimomura, K., Watanabe, S., Takagi, M."Construction of <em>in vitro</em> patient‑derived tumor models to evaluate anticancer agents and cancer immunotherapy". Oncology Letters 21.5 (2021): 406.
Chicago
Takahashi, N., Higa, A., Hiyama, G., Tamura, H., Hoshi, H., Dobashi, Y., Katahira, K., Ishihara, H., Takagi, K., Goda, K., Okabe, N., Muto, S., Suzuki, H., Shimomura, K., Watanabe, S., Takagi, M."Construction of <em>in vitro</em> patient‑derived tumor models to evaluate anticancer agents and cancer immunotherapy". Oncology Letters 21, no. 5 (2021): 406. https://doi.org/10.3892/ol.2021.12667